



cap

Protocol for the Examination of Specimens From Patients With Carcinoma of the Anus

Protocol applies to all invasive carcinomas of the anal canal. Perianal tumors are not included.

Based on AJCC/UICC TNM, 7th edition

Protocol web posting date: June 2012

Procedures

- Excisional Biopsy
- Local Excision (Transanal Disk Incision)
- Abdominoperineal Resection

Authors

Laura H. Tang, MD, PhD, FCAP*

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

Jordan Berlin, MD

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

Philip Branton, MD, FCAP

Department of Pathology, Inova Fairfax Hospital, Falls Church, VA

Lawrence J. Burgart, MD, FCAP

Allina Laboratories, Abbott Northwestern Hospital, Minneapolis, MN

David K. Carter, MD, FCAP

Department of Pathology, St. Mary's/Duluth Clinic Health System, Duluth, MN

Carolyn C. Compton, MD, PhD, FCAP

Critical Path Institute, Tucson, AZ

Patrick Fitzgibbons, MD, FCAP

Department of Pathology, St. Jude Medical Center, Fullerton, CA

Wendy Frankel, MD, FCAP

Department of Pathology, Ohio State University Medical Center, Columbus, OH

John Jessup, MD

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD

Sanjay Kakar, MD, FCAP

Department of Pathology, University of California San Francisco and the Veterans Affairs Medical Center, San Francisco, CA

Bruce Minsky, MD

Department of Radiation Oncology, University of Chicago, Chicago, IL

Raouf Nakhleh, MD, FCAP

Department of Pathology, Mayo Clinic, Jacksonville, FL

Kay Washington, MD, PhD, FCAP†

Department of Pathology, Vanderbilt University Medical Center, Nashville, TN

For the Members of the Cancer Committee, College of American Pathologists

* Denotes primary author. † Denotes senior author. All other contributing authors are listed alphabetically.

Previous contributor: R. R. Rickert, MD

© 2012 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.

Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.

CAP Anus Protocol Revision History

Version Code

The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: Anus 3.2.0.0

Summary of Changes

The following changes have been made since the February 2011 release.

Title page: updated to exclude perianal tumors.

Excisional Biopsy or Local Excision (Transanal Disk Excision)

Tumor Site

"Anal margin" was removed.

Histologic Type

"Small cell carcinoma" was replaced with the following:

- High-grade neuroendocrine carcinoma
- Large cell neuroendocrine carcinoma
- Small cell neuroendocrine carcinoma

Abdominoperineal Resection

Tumor Site

"Anal margin" was removed.

Histologic Type

"Small cell carcinoma" was replaced with the following:

- High-grade neuroendocrine carcinoma
- Large cell neuroendocrine carcinoma
- Small cell neuroendocrine carcinoma

Margins

The following was added:

Other Margin(s) (required only if applicable)

Specify margin(s): _____

- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma

Explanatory Notes

Histologic Type: Histologic types were updated, as detailed above.

References

Reference #3 was updated.

Surgical Pathology Cancer Case Summary

Protocol web posting date: June 2012

ANUS: Excisional Biopsy or Local Excision (Transanal Disk Excision)**Select a single response unless otherwise indicated.****Specimen (select all that apply)**

- Anal canal
 Anorectal junction
 Rectum
 Perianal skin
 Other (specify): _____
 Not specified

Procedure

- Excisional biopsy (polypectomy)
 Local excision (transanal disk excision)
 Other (specify): _____
 Not specified

Specimen Integrity (Note A)

- Intact
 Fragmented
 + Number of pieces in fragmented specimens: ____
 Other (specify): _____

Tumor Site (Note B)

- Anal canal
 Anorectal junction
 Anus, not otherwise specified
 Unknown
 Other (specify): _____

Tumor Size

- Greatest dimension: ____ cm
 + Additional dimensions: ____x____ cm
 Cannot be determined (see Comment)

Histologic Type (Note C)

- Squamous cell carcinoma
 Adenocarcinoma
 Mucinous adenocarcinoma
 High-grade neuroendocrine carcinoma
 Large cell neuroendocrine carcinoma
 Small cell neuroendocrine carcinoma
 Undifferentiated carcinoma
 Paget disease
 Other (specify): _____

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Histologic Grade (Note D)

- Not applicable
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- G4: Undifferentiated
- Other (specify): _____

Microscopic Tumor Extension

- Cannot be assessed
- No evidence of primary tumor
- Carcinoma in situ
- Tumor invades lamina propria
- Tumor invades muscularis mucosae
- Tumor invades submucosa
- Tumor invades sphincter muscle
- Tumor invades perianal skin

Margins (select all that apply)

- Cannot be assessed
- Margins uninvolved by invasive carcinoma
 - Distance of invasive carcinoma from closest margin: ___ mm or ___ cm
 - Specify margin (if possible): _____
 - Carcinoma in situ absent at mucosal margin
 - Carcinoma in situ present at mucosal margin
- Margin(s) involved by invasive carcinoma
 - Specify margin (if possible): _____
- Not applicable (specify reason): _____

Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy) (Note E)

- No prior treatment
- Present
 - + Complete response (no viable tumor cells, grade 0)
 - + Moderate response (single cells or small groups of tumor cells, grade 1)
 - + Minimal response (residual tumor outgrown by fibrosis, grade 2)
- No definite response identified (grade 3, poor or no response; extensive residual tumor)
- Not known

+ Lymph-Vascular Invasion

- + Not identified
- + Present
- + Indeterminate

+ Perineural Invasion

- + Not identified
- + Present
- + Indeterminate

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Pathologic Staging (pTNM) (Note F)

TNM Descriptors (required only if applicable) (select all that apply)

- m (multiple primary tumors)
- r (recurrent)
- y (posttreatment)

Primary Tumor (pT)

- pTX: Cannot be assessed
- pT0: No evidence of primary tumor
- pTis: Carcinoma in situ
- pT1: Tumor 2 cm or less in greatest dimension
- pT2: Tumor more than 2 cm but not more than 5 cm in greatest dimension
- pT3: Tumor more than 5 cm in greatest dimension
- pT4: Tumor of any size with invasion of adjacent organ(s); eg, vagina, urethra, bladder (involvement of sphincter muscles alone is not classified as T4).

+ Additional Pathologic Findings (select all that apply) (Note G)

- + None identified
- + Crohn disease
- + Condyloma accuminatum
- + Dysplasia
- + Associated rectal carcinoma (Paget disease)
- + Other (specify): _____

+ Ancillary Studies (Note H)

- + Specify: _____
- + Not performed

+ Clinical History (select all that apply) (Note I)

- + Solid organ transplantation
- + HIV/AIDS
- + Human papillomavirus infection
- + Crohn disease
- + Neoadjuvant therapy (specify type, if known): _____
- + Other (specify): _____
- + Not known

+ Comment(s)

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Surgical Pathology Cancer Case Summary

Protocol web posting date: June 2012

ANUS: Abdominoperineal Resection**Select a single response unless otherwise indicated.****Specimen (select all that apply)**

- Anal canal
 Anorectal junction
 Rectum
 Perianal skin
 Other (specify): _____
 Not specified

Procedure

- Abdominoperineal resection
 Other (specify): _____
 Not specified

Tumor Site (select all that apply) (Note B)

- Anal canal
 Anorectal junction
 Anus, not otherwise specified
 Unknown
 Other (specify): _____

Tumor Size

- Greatest dimension: ___ cm
 + Additional dimensions: ___ x ___ cm
 Cannot be determined (see Comment)

Histologic Type (Note C)

- Squamous cell carcinoma
 Adenocarcinoma
 Mucinous adenocarcinoma
 High-grade neuroendocrine carcinoma
 - Large cell neuroendocrine carcinoma
 - Small cell neuroendocrine carcinoma Undifferentiated carcinoma
 Paget disease
 Other (specify): _____
 Carcinoma, type cannot be determined

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Histologic Grade (Note D)

- Not applicable
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- G4: Undifferentiated
- Other (specify): _____

Microscopic Tumor Extension

- Cannot be assessed
- No evidence of primary tumor
- Carcinoma in situ
- Tumor invades lamina propria
- Tumor invades muscularis mucosae
- Tumor invades submucosa
- Tumor invades into but not through sphincter muscle
- Tumor invades into but not through muscularis propria of rectum
- Tumor invades through sphincter muscle into perianal or perirectal soft tissue without involvement of adjacent structures
- Tumor directly invades adjacent structures (specify): _____
- Tumor invades perianal skin

Margins (select all that apply)

If all margins uninvolved by invasive carcinoma:

Distance of invasive carcinoma from closest margin: ___ mm or cm

Specify margin: _____

Proximal Margin

- Cannot be assessed
- Uninvolved by invasive carcinoma
 - Carcinoma in situ absent at mucosal margin
 - Carcinoma in situ present at mucosal margin
- Involved by invasive carcinoma

Distal Margin

- Cannot be assessed
- Uninvolved by invasive carcinoma
 - Carcinoma in situ absent at mucosal margin
 - Carcinoma in situ present at mucosal margin
- Involved by invasive carcinoma

Circumferential (Radial) Margin

- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Other Margin(s) (required only if applicable)

Specify margin(s): _____

- Cannot be assessed
- Uninvolved by invasive carcinoma
- Involved by invasive carcinoma

Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy) (select all that apply)
(Note E)

- No prior treatment
- Present
 - + Complete response (no viable tumor cells, grade 0)
 - + Moderate response (single cells or small groups of tumor cells, grade 1)
 - + Minimal response (residual tumor outgrown by fibrosis, grade 2)
- No definite response identified (grade 3, poor or no response; extensive residual tumor)
- Not known

+ Lymph-Vascular Invasion

- + Not identified
- + Present
- + Indeterminate

+ Perineural Invasion

- + Not identified
- + Present
- + Indeterminate

Pathologic Staging (pTNM) (Note F)

TNM Descriptors (required only if applicable) (select all that apply)

- m (multiple primary tumors)
- r (recurrent)
- y (posttreatment)

Primary Tumor (pT)

- pTX: Cannot be assessed
- pT0: No evidence of primary tumor
- pTis: Carcinoma in situ
- pT1: Tumor 2 cm or less in greatest dimension
- pT2: Tumor more than 2 cm but not more than 5 cm in greatest dimension
- pT3: Tumor more than 5 cm in greatest dimension
- pT4: Tumor of any size with invasion of adjacent organ(s); eg, vagina, urethra, bladder (involvement of sphincter muscles alone is not classified as T4).

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
- pN0: No regional lymph node metastasis
- pN1: Metastasis in perirectal lymph nodes
- pN2: Metastasis in unilateral internal iliac and/or inguinal lymph node(s)
- pN3: Metastasis in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal lymph nodes
- No nodes submitted or found

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Number of Lymph Nodes Examined

Specify: ____

___ Number cannot be determined (explain): _____

Number of Lymph Nodes Involved

Specify: ____

___ Number cannot be determined (explain): _____

Distant Metastasis (pM)

___ Not applicable

___ pM1: Distant metastasis

+ Specify site(s), if known: _____

+ Additional Pathologic Findings (select all that apply) (Note G)

+ ___ None identified

+ ___ Crohn disease

+ ___ Condyloma accuminatum

+ ___ Dysplasia

+ ___ Associated rectal carcinoma (Paget disease)

+ ___ Other (specify): _____

+ Ancillary Studies (Note H)

+ Specify: _____

+ Clinical History (select all that apply) (Note I)

+ ___ Solid organ transplantation

+ ___ HIV/AIDS

+ ___ Human papillomavirus infection

+ ___ Crohn disease

+ ___ Neoadjuvant therapy (specify type if known): _____

+ ___ Other (specify): _____

+ ___ Not known

+ Comment(s)

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Explanatory Notes

A. Specimen Integrity and Handling

For specimens from local excision procedures, all relevant margins, including the deep resection margin, should be inked. Evaluation of margins and invasion is facilitated if the specimen is pinned before fixation in formalin.

B. Location

Documentation of tumor location within the anal canal is important for purposes of stage assignment. Because of possible differences in staging and regional lymph nodes at risk of metastasis among cancers of the anal canal, the rectum, and the perianal skin, it is essential to assure that the anatomic site of the tumor is the anal canal. For the pathologist, however, the documentation of location may be problematic. Currently, most anal canal carcinomas are managed successfully without surgery, using combination chemotherapy and radiation therapy¹; and resection specimens of anal tumors are seen only infrequently (primarily for small anal margin lesions or after failure of other treatment modalities). Although histological diagnosis is almost always performed on small biopsies, determination of the primary tumor location from biopsy specimens may be difficult or impossible. Therefore, documentation of anatomic site often requires clinical correlation.

A major problem complicating determination of anatomic site clinically or pathologically is the controversy over the anatomic definition of the anal canal itself. The surgical definition of the anal canal is the one most widely accepted for practical reasons and is the preferred definition of the American Joint Committee on Cancer (AJCC).² However, it is based on clinically identifiable landmarks that are difficult or impossible for the pathologist to locate. By this definition, the anal canal begins at the point where the rectum enters the puborectalis sling at the apex of the anal sphincter complex, a landmark that is palpable in vivo on digital exam as the anorectal ring. The termination of the anal canal is defined as the squamous mucocutaneous junction (ie, the junction of the distal squamous mucosa of the anal canal with the perianal hair-bearing skin).² Thus defined, the anal canal (Figure 1) contains 3 epithelial zones: a proximal narrow zone (approximately 1 to 2 cm) of rectal-type glandular mucosa, an anal transition zone of variable length interposed between colorectal mucosa and squamous epithelium, and a squamous epithelial zone lacking skin appendages. The squamous zone gradually merges into the perianal skin, which contains hair follicles, sweat glands, and sebaceous glands. The anal transition zone may contain a variety of epithelial types, including multilayered transitional mucosa resembling squamous metaplasia or urothelium, which is often present at the dentate line. Anal glands may be found subjacent to the mucosa extending across the internal sphincter in the region of the dentate line.




Figure 1. Anatomy of the anal canal. From Greene et al.¹⁷ Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

Tumors involving the anorectal junction should be classified as rectal cancers if the epicenter is more than 2 cm proximal to the dentate line and as anal cancers if the epicenter is 2 cm or less from the dentate line.²

Cancers that arise in the perianal skin are termed “perianal cancers” and are biologically similar to other skin tumors. They are staged according to the classification for cancers of the skin² (see CAP protocols for skin).

C. Histologic Type

For consistency in reporting, the histologic classification proposed by the World Health Organization (WHO) is recommended.³ However, this protocol does not preclude the use of other systems of classification or histologic types.

The great majority of carcinomas of the anus are squamous cell carcinomas.⁴ The previous edition of the WHO classification included 3 subtypes of squamous cell carcinoma (SCC): large cell keratinizing, large cell nonkeratinizing, and basaloid. However, because most SCCs of the anal canal show more than one subtype, the diagnostic reproducibility of these subtypes has been low. Furthermore, no significant prognostic differences between subtypes have consistently been established, although the basaloid subtype of squamous cell carcinoma may be associated with a higher risk of distant metastasis.⁵ Therefore, the WHO now recommends that the generic diagnostic term “squamous cell carcinoma” be used for all squamous malignancies of the anal canal. However, additional descriptive comment regarding specific histologic features, such as predominant cell size, basaloid features, degree of keratinization, or adjacent intraepithelial neoplasia, is encouraged. Prominent basaloid features and small tumor cell size are related to infection with “high-risk” human papilloma virus.³ SCC with a predominantly basaloid differentiation pattern was formerly known as cloacogenic carcinoma, but this term is now considered obsolete.

Two variants of SCC of the anal canal deserve note because they differ in prognosis from typical squamous tumors. One is verrucous carcinoma (also known as giant condyloma or Buschke-Lowenstein tumor), which resembles a condyloma macroscopically but is larger and fails to respond to conservative therapy. These lesions are regarded as biologic intermediates between condylomas and SCCs, with a better prognosis than SCC. However, nearly half of these lesions undergo malignant

transformation. Another important variant is SCC with mucinous microcysts (well-formed cystic spaces containing Alcian blue- or PAS-stainable mucin). This entity has an unfavorable prognosis as compared with that of SCC.³

Finally, two rare types of anal canal carcinoma, anaplastic carcinoma and small cell carcinoma (high-grade neuroendocrine carcinoma), are tumors with aggressive biologic behavior and an unfavorable prognosis when compared with typical SCC. Tumors of the more distal anal canal and especially anal margin (mucocutaneous junction) are generally purely squamous in type and show fewer basaloid or glandular features.

WHO Classification of Carcinoma of the Anal Canal³

Intraepithelial neoplasia

 Squamous or transitional epithelium

 Glandular

 Paget disease

Carcinoma

 Squamous cell carcinoma

 Adenocarcinoma

 Mucinous adenocarcinoma

 High-grade neuroendocrine carcinoma

 Large cell neuroendocrine carcinoma

 Small cell neuroendocrine carcinoma[#]

 Undifferentiated carcinoma[#]

 Others

[#] By convention, these histologic types are assigned grade 4.

The term “carcinoma, NOS (not otherwise specified)” is not part of the WHO classification.

D. Histologic Grade

Histologic grades for anal canal squamous carcinoma are as follows:

Grade X Grade cannot be assessed

Grade 1 Well differentiated

Grade 2 Moderately differentiated

Grade 3 Poorly differentiated

If there are variations in the differentiation within the tumor, the highest (least favorable) grade is recorded as the overall grade.

Histologic grades for adenocarcinoma of the anal canal based on the proportion of gland formation by the tumor are suggested as follows:

Grade X Grade cannot be assessed

Grade 1 Well differentiated (greater than 95% of tumor composed of glands)

Grade 2 Moderately differentiated (50% to 95% of tumor composed of glands)

Grade 3 Poorly differentiated (less than 50% of tumor composed of glands)

Small cell carcinomas and tumors with no differentiation or minimal differentiation that is discernible only in rare, tiny foci (undifferentiated carcinomas by WHO classification) are categorized as grade 4.

E. Treatment Effect

Response of tumor to previous chemotherapy or radiation therapy should be reported. Although grading systems for tumor response have not been established, three-category systems generally provide good interobserver reproducibility.⁶ The following system is suggested:

Tumor Regression Grade

Description	Tumor Regression Grade
No viable cancer cells	0 (Complete response)
Single cells or small groups of cancer cells	1 (Moderate response)
Residual cancer outgrown by fibrosis	2 (Minimal response)
Minimal or no tumor kill; extensive residual cancer	3 (Poor response)

F. TNM and Anatomic Stage/Prognostic Groupings

The TNM staging system for anal carcinoma of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) is recommended by the protocol and shown below.² The primary tumor is staged according to its size and local extension, as determined by clinical or pathologic examination. For most histologic types of anal canal cancer, the diameter of the tumor correlates with the depth of penetration. The staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and anal glands, but excluding melanomas, low-grade neuroendocrine tumors (carcinoid tumors), and sarcomas.

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically infeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or after initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor before multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

T Category Considerations

T categories for anal canal cancer are illustrated in Figures 2 through 5.

T1




Figure 2. T1 is defined as tumor 2 cm or less in greatest dimension. From Greene et al.¹⁷ Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, www.springerlink.com.




Figure 3. T2 is defined as tumor measuring more than 2 cm but 5 cm or less in greatest dimension. From Greene et al.¹⁷ Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, www.springerlink.com.




Figure 4. T3 is defined as tumor measuring more than 5 cm in greatest dimension. From Greene et al.¹⁷ Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

T4




Figure 5. T4 is defined as tumor of any size invading adjacent organs such as vagina (illustrated), urethra, or bladder. From Greene et al.¹⁷ Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

N Category Considerations

Regional lymph nodes (N) (Figure 6) consist of the perirectal (anorectal, perirectal, and lateral sacral), the internal iliac (hypogastric), and the inguinal (superficial and deep femoral).² All other nodal groups represent sites of distant metastasis (M). The sites of regional node involvement correspond to the local lymphatic drainage, above to the rectal ampulla and below to the perineum. Tumors that arise in the anal canal usually spread initially to the anorectal and perirectal nodes, and those that arise at the anal margin spread to the superficial inguinal nodes.




Figure 6. Regional lymph nodes of the anal canal. From Greene et al.¹⁷ Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

Primary Tumor (T)

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- Tis Carcinoma in situ
- T1 Tumor 2 cm or less in greatest dimension
- T2 Tumor more than 2 cm but not more than 5 cm in greatest dimension
- T3 Tumor more than 5 cm in greatest dimension
- T4 Tumor of any size invades adjacent organ(s), eg, vagina, urethra, bladder[#]

[#]Direct invasion of the rectal wall, perianal skin, subcutaneous tissue, or the sphincter muscle is not classified as T4.

Regional Lymph Nodes (N)

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis[#]
- N1 Metastasis in perirectal lymph node(s)
- N2 Metastasis in unilateral internal iliac and/or inguinal lymph node(s)
- N3 Metastasis in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal lymph nodes

Distant Metastasis (M)

- M0 No distant metastasis
- M1 Distant metastasis

Stage Groupings

Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
	T3	N0	M0
Stage IIIA	T1	N1	M0
	T2	N1	M0
	T3	N1	M0
	T4	N0	M0

Stage IIIB	T4	N1	M0
	Any T	N2	M0
	Any T	N3	M0
Stage IV	Any T	Any N	M1

Vessel Invasion

By AJCC/UICC convention, vessel invasion (lymphatic or venous) does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

G. Additional Findings

Predisposing conditions to anal canal carcinoma that may be found in the pathologic specimen include condyloma accuminatum associated with human papilloma virus infection.⁷ Squamous intraepithelial neoplasia is recognized as a precursor lesion for squamous cell carcinoma of the anal canal,⁸ and its presence should be reported. Both adenocarcinomas and squamous cell carcinomas have been reported in the setting of chronic anorectal fistulae arising in long-standing Crohn disease,⁹ although the association of benign inflammatory lesions and anal cancer remains controversial.^{10,11}

H. Ancillary Studies

Immunohistochemistry may be helpful in establishing tumor type for poorly differentiated carcinomas; squamous cell carcinomas of the anal canal express cytokeratin (CK) 7, CK5/6, p53,¹² and p63,¹³ but are negative for CK20. In contrast, anal gland carcinomas are mucin positive and express CK 20 and CK7, but are negative for CK5/6 and p63.^{12,14}

Immunohistochemical studies may also aid in distinguishing primary anal Paget disease from secondary Paget disease of the perianal area, which is associated with colorectal and anal canal carcinoma. CK7 expression is a sensitive method for detection of both primary and secondary Paget cells within involved anal and perianal epithelium. In addition, however, the specific immunophenotype of Paget cells has been shown to correlate with pathogenesis and may be important in patient management. Demonstration of CK20 expression has been shown to identify Paget disease that is likely to be associated with underlying rectal adenocarcinoma (presenting either synchronously or metachronously). In contrast, Paget cells that do not express CK20 but instead are positive for gross cystic disease fluid protein (GCDFP), a marker for apocrine differentiation, are likely to represent primary cutaneous intraepithelial malignancy.^{3,8,15}

I. Clinical History

Predisposing conditions for anal canal carcinomas include immunosuppression, most commonly from solid organ transplantation, or HIV/AIDS infection.¹⁶ The association between human papilloma virus infection and anal cancer has been firmly established.⁷

References

1. Engstrom PF, Benson AB 3rd, Chen Y-J, et al. Anal canal cancer clinical practice guidelines in oncology. *J Natl Compr Cancer Netw*. Jul 2005;3(4):510-515.
2. Edge SB, Byrd DR, Carducci MA, Compton CC, eds. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2009.
3. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. *WHO Classification of Tumours of the Digestive System*. Geneva, Switzerland: WHO Press; 2010.
4. Hatzaras I, Abir F, Kozol R, Sullivan P, Longo WE. The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000. *Conn Med*. 2005;69(5):261-265.
5. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. *Int J Radiat Oncol Biol Phys*. 2007;68(3):794-800.
6. Ryan R, Gibbons D, Hyland JMP, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology*. 2005;47:141-146.

7. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. *Cancer*. 2004;101(2):270-280.
8. Shepherd NA. Anal intraepithelial neoplasia and other neoplastic precursor lesions of the anal canal and perianal region. *Gastroenterol Clin North Am*. 2007;36(4):969-987.
9. Ky A, Sohn H, Weinstein MA, Korelitz BI. Carcinoma arising in anorectal fistulas of Crohn's disease. *Dis Colon Rectum*. 1998;41:992-996.
10. Frisch M, Olsen JH, Bautz A, Melbye M. Benign anal lesions and the risk of anal cancer. *New Engl J Med*. 1994;331:300-302.
11. Nordenvall C, Nyren O, Ye W. Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. *Gut*. May 2006;55(5):703-707.
12. Balachandra B, Marcus V, Jass JR. Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist. *Histopathology*. Jan 2007;50(1):163-174.
13. Owens SR, Greenson JK. Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. *Am J Surg Pathol*. 2007;31(2):285-290.
14. Lisovsky M, Patel K, Cymes K, Chase D, Bhuiya T, Morgenstern N. Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. *Arch Pathol Lab Med*. 2007;131(8):1304-1311.
15. Goldblum JR, Hart WR. Perianal Paget's disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. *Am J Surg Pathol*. 1998;22:170-179.
16. Uronis HE, Bendell JC. Anal cancer: an overview. *Oncologist*. May 2007;12(5):524-534.
17. Greene FL, Compton, CC, Fritz AG, et al, eds. *AJCC Cancer Staging Atlas*. New York: Springer; 2006.